Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/16/19 | Current report filing |
|
27 | ||
| 07/15/19 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 07/15/19 | Current report filing |
|
7 | ||
| 06/20/19 | Current report filing |
|
3 | ||
| 06/04/19 | Current report filing |
|
5 | ||
| 06/03/19 | Current report filing |
|
3 | ||
| 05/14/19 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
45 | |
| 05/13/19 | Current report filing |
|
7 | ||
| 04/30/19 | Definitive proxy statements |
|
47 | ||
| 04/19/19 | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
47 |